{
    "paper_id": "PMC7105280",
    "metadata": {
        "title": "Clinical trials on drug repositioning for COVID-19 treatment",
        "authors": [
            {
                "first": "Sandro",
                "middle": [
                    "G.",
                    "Viveiros"
                ],
                "last": "Rosa",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Wilson",
                "middle": [
                    "C."
                ],
                "last": "Santos",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "We performed a search on March 12, 2020, at the clinicaltrials. gov database, with the descriptor [coronavirus] in the simple search field \u201cconditions or disease\u201d search, without restrictions on languages, disease conditions, results, or locations. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the study period; describe the patient\u2019s clinical conditions; and interventions utilize medicines already studied or approved for any other disease in patients with COVID-19. ClinicalTrials.gov is a resource from the US National Library of Medicine, and it contains clinical studies conducted by 209 countries.",
            "cite_spans": [],
            "section": "METHODS",
            "ref_spans": []
        },
        {
            "text": "We identified 24 clinical trials (Table 1), in which 19 studies were at clinical phases 2, 3, or 4. The pharmaceutical interventions found for COVID-19 treatment include human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, oseltamivir, favipiravir, carrimycin, methylprednisolone, bevacizumab, thalidomide, vitamin C, pirfenidone, bromhexine, fingolimod, danoprevir, ritonavir, darunavir, cobicistat, lopinavir, xiyanping, and traditional Chinese medicines (TCM).",
            "cite_spans": [],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 34,
                    "end": 41,
                    "mention": "Table 1",
                    "ref_id": null
                }
            ]
        },
        {
            "text": "Chloroquine and hydroxychloroquine are antimalarial drugs. They have antiviral effects against human immuno-deficiency virus (HIV), namely by inhibiting virus entry into host cells. Another antiviral mechanism is related to the post-translation alteration of newly synthesized proteins via glycosylation inhibition (12). Hydroxychloroquine is already being used in clinical trials on acquired immune deficiency syndrome (AIDS) treatment (13). In a recent trial with patients on COVID-19 treatment (14), 100% of patients treated with hydroxychloroquine in combination with the macrolide antibiotic azithromycin were virologically cured comparing with 57.1% in patients treated with hydroxychloroquine alone, and 12.5% in the control group. Currently, chloroquine and hydroxychloroquine will be tested (15,16) in patients with pneumonia caused by 2019-nCoV and chloroquine as preventative medicine for COVID-19, as shown in Table 1.",
            "cite_spans": [
                {
                    "start": 316,
                    "end": 318,
                    "mention": "12",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 438,
                    "end": 440,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 498,
                    "end": 500,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 801,
                    "end": 803,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 804,
                    "end": 806,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 922,
                    "end": 929,
                    "mention": "Table 1",
                    "ref_id": null
                }
            ]
        },
        {
            "text": "Immunoglobulins are useful in several diseases, such as idiopathic thrombocytopenia purpura (ITP), Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and in multiple neurological autoimmune disorders refractory to standard immunosuppressive treatments (17). Broadly neutralizing antibodies can recognize a wide variety of glycoproteins (GPs) in virus surfaces or the protein shell of a non-enveloped virus. However, HIV-1, dengue virus (DENV), influenza viruses, hepatitis C virus (HCV), and Ebola virus (EBOV) can mutate superficial GPs in order to evade the antibody response, an obstacle in the development of new therapies against such infections (18). Trial NCT04261426 (19) is utilizing human immunoglobulin in patients with pneumonia caused by 2019-nCoV (Table 1).",
            "cite_spans": [
                {
                    "start": 309,
                    "end": 311,
                    "mention": "17",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 708,
                    "end": 710,
                    "mention": "18",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 732,
                    "end": 734,
                    "mention": "19",
                    "ref_id": "BIBREF10"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 818,
                    "end": 825,
                    "mention": "Table 1",
                    "ref_id": null
                }
            ]
        },
        {
            "text": "Two clinical studies refer to the use of remdesivir in severe (20) or mild (21) respiratory infections by SARS-CoV-2. Remdesivir is a nucleotide analog inhibitor of the EBOV RNA-polymerase RNA-dependent (RdRp). Dyer et al. 2019 (22) described preliminary findings of a mortality rate of 33% in 499 patients treated with remdesivir against the EBOV disease in early infection stages. The same authors noted a mortality rate of 75% (almost 1 900 people) of non-treated infected patients during the same epidemic period (22). Wang et al. 2020 (23) presented data showing that remdesivir is effective against the 2019-nCoV in Vero E6 cells (EC90 1.76 \u03bcM). The suggested mechanism for remdesivir involves the host cells\u2019 post-entry stage (23).",
            "cite_spans": [
                {
                    "start": 63,
                    "end": 65,
                    "mention": "20",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 76,
                    "end": 78,
                    "mention": "21",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 229,
                    "end": 231,
                    "mention": "22",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 518,
                    "end": 520,
                    "mention": "22",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 541,
                    "end": 543,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 734,
                    "end": 736,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Arbidol, also known as umifenovir, is approved in Russia and China for the treatment of influenza virus infections; it does not have significant adverse effects and is patented for SARS treatment (24). As shown in Table 1, four clinical trials will be conducted for COVID-19 treatment: one with arbidol in comparison with the basic treatment (25), and the other three studies comparing effects with oseltamivir (26,27), lopinavir-ritonavir (27), and carrimycin (28). The arbidol anti-viral mechanism against influenza A and B involves viral fusion inhibition with the targeted membrane, which blocks virus entry into the cell (24). Oseltamivir is another drug approved for influenza A and B treatment; it inhibits the viral neuraminidase and, consequently, blocks the release of viral particles from host cells, reducing the spread in the respiratory tract (29). Additionally, the use of oseltamivir was already reported during the COVID-19 epidemic in China, either with or without antibiotics and corticosteroids (30). Oseltamivir is also used in a clinical trial with multiple combinations with chloroquine and favipiravir (31), a nucleoside analog that is well-known as a broad-spectrum antiviral drug; it has shown (23) an EC50 of 61.88 \u03bcM against SARS-CoV-2 and low toxicity (CC50 >400 \u03bcM).",
            "cite_spans": [
                {
                    "start": 197,
                    "end": 199,
                    "mention": "24",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 343,
                    "end": 345,
                    "mention": "25",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 412,
                    "end": 414,
                    "mention": "26",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 415,
                    "end": 417,
                    "mention": "27",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 441,
                    "end": 443,
                    "mention": "27",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 462,
                    "end": 464,
                    "mention": "28",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 627,
                    "end": 629,
                    "mention": "24",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 858,
                    "end": 860,
                    "mention": "29",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1016,
                    "end": 1018,
                    "mention": "30",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 1127,
                    "end": 1129,
                    "mention": "31",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 1221,
                    "end": 1223,
                    "mention": "23",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 214,
                    "end": 221,
                    "mention": "Table 1",
                    "ref_id": null
                }
            ]
        },
        {
            "text": "The lopinavir-ritonavir combination is approved for AIDS treatment in several countries. Both drugs are HIV protease inhibitors, but ritonavir is also a cytochrome P450 and GP inhibitor, a fact that endorses the lopinavir pharmacokinetic and pharmacodynamic activities against HIV (32). Such a combination, plus \u03b2-1b interferon, is in phase 2 for the MERS treatment (33). Several trials involve lopinavir-ritonavir treatment in comparison with the use of other drugs for COVID-19: arbidol (26,27), carrimycin (28), TCM (34,35), xiyanping (36,37), danoprevir-ritonavir (38) and interferon inhalation (34,38). Nevertheless, one previous article argued that in a clinical trial with 199 patients with laboratory-confirmed SARS-CoV-2 infection, the lopinavir-ritonavir combination was not associated with clinical improvement comparing with standard care procedures (39).",
            "cite_spans": [
                {
                    "start": 282,
                    "end": 284,
                    "mention": "32",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 367,
                    "end": 369,
                    "mention": "33",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 490,
                    "end": 492,
                    "mention": "26",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 493,
                    "end": 495,
                    "mention": "27",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 510,
                    "end": 512,
                    "mention": "28",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 520,
                    "end": 522,
                    "mention": "34",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 523,
                    "end": 525,
                    "mention": "35",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 539,
                    "end": 541,
                    "mention": "36",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 542,
                    "end": 544,
                    "mention": "37",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 569,
                    "end": 571,
                    "mention": "38",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 600,
                    "end": 602,
                    "mention": "34",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 603,
                    "end": 605,
                    "mention": "38",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 863,
                    "end": 865,
                    "mention": "39",
                    "ref_id": "BIBREF32"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Carrimycin is a macrolide antibiotic with effects against some gram-positive bacteria and in vitro effects on Mycobacterium tuberculosis (40).",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 140,
                    "mention": "40",
                    "ref_id": "BIBREF34"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Danoprevir is an HCV NS3 protease inhibitor approved in China for the treatment of non-cirrhotic genotype 1b chronic hepatitis C, in combination with ritonavir, peginterferon-a, and ribavirin (41).",
            "cite_spans": [
                {
                    "start": 193,
                    "end": 195,
                    "mention": "41",
                    "ref_id": "BIBREF35"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Traditional Chinese medicine (TCM) uses phytotherapeutic formulations such as teas, pills, powders or tinctures, and cultural components that originated 5000 years ago in Chinese medicine (42). TCMs were already used for SARS-CoV infection in 2002 as coadjuvant therapy with the enhancement of patients\u2019 symptoms, increased oxyhemoglobin arterial saturation; they proved useful in the early stages of this infection (42).",
            "cite_spans": [
                {
                    "start": 189,
                    "end": 191,
                    "mention": "42",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 417,
                    "end": 419,
                    "mention": "42",
                    "ref_id": "BIBREF36"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Interferons (IFNs) are proteins that bind to cellular surfaces\u2019 receptors and initiate JAK-STAT signaling cascades, with transcriptional regulation of genes controlled by interferons and effects against some viruses like hepatitis B virus and HCV (43).",
            "cite_spans": [
                {
                    "start": 248,
                    "end": 250,
                    "mention": "43",
                    "ref_id": "BIBREF37"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Xiyanping is a TCM preparation with andrographolide as a principal component; it has significant antibacterial and antiviral effects (44).",
            "cite_spans": [
                {
                    "start": 134,
                    "end": 136,
                    "mention": "44",
                    "ref_id": "BIBREF38"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Darunavir, in combination with cobicistat, will be used in trial number NCT04252274 (45) in patients with COVID-19 pneumonia. The United States Food and Drug Administration (FDA) currently approves such a combination in AIDS treatment. Darunavir is another HIV protease inhibitor, and cobicistat, like ritonavir, is a booster for enhancing the pharmacokinetics and pharmacodynamics of darunavir by cytochrome P450 (CYP3A) inhibition (46,47).",
            "cite_spans": [
                {
                    "start": 85,
                    "end": 87,
                    "mention": "45",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 434,
                    "end": 436,
                    "mention": "46",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 437,
                    "end": 439,
                    "mention": "47",
                    "ref_id": "BIBREF41"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Recombinant human interferon \u03b12\u03b2 is described to have inhibitory effects on MERS-CoV and SARS-CoV (48), and the purpose of the clinical trials found for this paper is to evaluate the efficacy and safety of recombinant human interferon \u03b12\u03b2 in treating patients with new coronavirus infection (49).",
            "cite_spans": [
                {
                    "start": 99,
                    "end": 101,
                    "mention": "48",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 292,
                    "end": 294,
                    "mention": "49",
                    "ref_id": "BIBREF43"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Thalidomide will be used in two trials against COVID-19 (49, 50). Thalidomide has an anti-inflammatory action due to its ability to speed up the degradation of messenger RNA in blood cells and thus reduce tumor necrosis factor-\u03b1 (TNF\u03b1). Furthermore, thalidomide can increase the secretion of interleukins, such as IL-12, and activate natural killer cells (51).",
            "cite_spans": [
                {
                    "start": 57,
                    "end": 59,
                    "mention": "49",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 61,
                    "end": 63,
                    "mention": "50",
                    "ref_id": "BIBREF45"
                },
                {
                    "start": 356,
                    "end": 358,
                    "mention": "51",
                    "ref_id": "BIBREF46"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The corticosteroid methylprednisolone will be tested against COVID-19 (52). Long et al. 2016 (53) reported that corticosteroid therapy (methylprednisolone, dexamethasone, and hydrocortisone) is beneficial in treating SARS-CoV patients; it significantly prolongs the survival time of clinical cases. Nevertheless, other authors described the use of corticosteroids in the early stages of SARS infection with increasing values of viral load (54). Furthermore, studies with corticosteroids in the adjuvant therapy of MERS-CoV infection were unable to prove efficacy because all patients died (55). Methylprednisolone has already been used in COVID-19 patients in combination with antibiotics, oseltamivir, and oxygen therapy (56).",
            "cite_spans": [
                {
                    "start": 71,
                    "end": 73,
                    "mention": "52",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 94,
                    "end": 96,
                    "mention": "53",
                    "ref_id": "BIBREF48"
                },
                {
                    "start": 440,
                    "end": 442,
                    "mention": "54",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 590,
                    "end": 592,
                    "mention": "55",
                    "ref_id": "BIBREF50"
                },
                {
                    "start": 723,
                    "end": 725,
                    "mention": "56",
                    "ref_id": "BIBREF51"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Finally, vitamin C (ascorbic acid), pirfenidone, bevacizumab, fingolimod, and bromhexine hydrochloride are going to be tested on COVID-19 (57-61). Vitamin C has antioxidant activity and may reduce oxidative stress and inflammation (57,62), effects that improve vasopressor synthesis, enhance immune cell function, improve endovascular function, and provide epigenetic immunologic modifications. Clinical trials have demonstrated promising data on mortality improvement in sepsis, but more extensive studies are necessary to validate these conclusions (63). Pirfenidone has been used in the treatment of idiopathic pulmonary fibrosis diseases due to anti-inflammatory and anti-oxidant effects, namely by inhibiting IL-1\u03b2 and IL-4 (58). Trial NCT04282902 claimed (58) that anti-inflammatory effects may be helpful in SARS-CoV-2 infection. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) (59,63), and it may reduce the levels of VEGF caused by hypoxia, severe inflammation, and upregulation of the infected respiratory tract epithelium, all of which might suppress the edema in patients with COVID-19 (63). Fingolimod is a sphingosine-1-phosphate receptor regulator (FTY720) with an effective immunology modulator that is useful in multiple sclerosis (60). According to some pathological findings of pulmonary edema and hyaline membrane formation, the use of immune modulators, together with ventilator support, should be considered for severe patients to prevent the development of acute respiratory distress syndrome (ARDS). Study NCT04280588 aims to determine the efficacy of fingolimod for COVID-19 (60). Bromhexine is a transmembrane protease serine inhibitor; such a protease is responsible for the activation of S-glycoprotein of SARS-CoV and MERS-CoV for viral entry through the plasma membrane (61,64). One study (60) will evaluate the efficacy of bromhexine combined with standard treatment/standard treatment in patients with COVID-19.",
            "cite_spans": [
                {
                    "start": 139,
                    "end": 141,
                    "mention": "57",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 142,
                    "end": 144,
                    "mention": "61",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 232,
                    "end": 234,
                    "mention": "57",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 235,
                    "end": 237,
                    "mention": "62",
                    "ref_id": "BIBREF58"
                },
                {
                    "start": 552,
                    "end": 554,
                    "mention": "63",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 730,
                    "end": 732,
                    "mention": "58",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 762,
                    "end": 764,
                    "mention": "58",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 940,
                    "end": 942,
                    "mention": "59",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 943,
                    "end": 945,
                    "mention": "63",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 1153,
                    "end": 1155,
                    "mention": "63",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 1303,
                    "end": 1305,
                    "mention": "60",
                    "ref_id": "BIBREF56"
                },
                {
                    "start": 1655,
                    "end": 1657,
                    "mention": "60",
                    "ref_id": "BIBREF56"
                },
                {
                    "start": 1855,
                    "end": 1857,
                    "mention": "61",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 1858,
                    "end": 1860,
                    "mention": "64",
                    "ref_id": "BIBREF60"
                },
                {
                    "start": 1874,
                    "end": 1876,
                    "mention": "60",
                    "ref_id": "BIBREF56"
                }
            ],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "In conclusion, the WHO declared an epidemic of pneumonia caused by the SARS-CoV-2 in 2020. In this review, we found 24 clinical trials that have already started with the repositioning of more than 20 medicines for COVID-19 treatment, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, oseltamivir, thalidomide, methylprednisolone, bevacizumab, and TCM. The Hydroxychloroquine-azithromycin combination was the first drug repurposed with excellent results in clinical trials against SARS-CoV-2, but further, more extended studies, with a higher number of patients, are needed to confirm these results. Besides its limitations, repositioning clinical trials are still an attractive strategy: they may facilitate the discovery of new classes of medicines; they may reduce the costs and time to reach the market; there is an existing pharmaceutical supply chain for formulation and distribution; and there is the possibility of combinations with other drugs in treatments that are more effective than monotherapy. Most of the studies found in this article are scheduled to end in 2020, and we hope these repositioning trials may help to find solutions for COVID-19 treatment by this year.",
            "cite_spans": [],
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or PAHO.",
            "cite_spans": [],
            "section": "Disclaimer.",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Novel Coronavirus (2019-nCoV) Situation Report \u2013 52",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Drug repurposing: progress, challenges and recommendations",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pushpakom",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Iorio",
                    "suffix": ""
                },
                {
                    "first": "PA",
                    "middle": [],
                    "last": "Eyers",
                    "suffix": ""
                },
                {
                    "first": "KJ",
                    "middle": [],
                    "last": "Escott",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hopper",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wells",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nat Rev Drug Discov",
            "volume": "18",
            "issn": "1",
            "pages": "41-58",
            "other_ids": {
                "DOI": [
                    "10.1038/nrd.2018.168"
                ]
            }
        },
        "BIBREF2": {
            "title": "Renovation as innovation: is repurposing the future of drug discovery research?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Neuberger",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Oraiopoulos",
                    "suffix": ""
                },
                {
                    "first": "DL",
                    "middle": [],
                    "last": "Drakeman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drug Discov Today",
            "volume": "24",
            "issn": "1",
            "pages": "1-3",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2018.06.012",
                    "10.1016/j.drudis.2018.06.012"
                ]
            }
        },
        "BIBREF3": {
            "title": "Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century",
            "authors": [
                {
                    "first": "JM",
                    "middle": [],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Antimicrob Agents",
            "volume": "30",
            "issn": "4",
            "pages": "297-308",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune activation in asymptomatic HIV-infected patients (HCQ01)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT01067417",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "JC",
                    "middle": [],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                },
                {
                    "first": "VT",
                    "middle": [],
                    "last": "Hoang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Meddeb",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mailhe",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF6": {
            "title": "Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04303507",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04261517",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Cherin",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Marie",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Michallet",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Pelus",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dantal",
                    "suffix": ""
                },
                {
                    "first": "JC",
                    "middle": [],
                    "last": "Crave",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Autoimmun Rev",
            "volume": "15",
            "issn": "1",
            "pages": "71-81",
            "other_ids": {
                "DOI": [
                    "10.1016/j.autrev.2015.09.002",
                    "10.1016/j.autrev.2015.09.002"
                ]
            }
        },
        "BIBREF9": {
            "title": "Broadly neutralizing antibodies for therapy of viral infections",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Varadarajan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Srinivasan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Maity",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ghosh",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Antib Technol J",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV infected pneumonia",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04261426",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Editorial \u2013 Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Perrella",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Carannante",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Berretta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rinaldi",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Maturo",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Rinaldi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Rev Med Pharmaco",
            "volume": "24",
            "issn": "",
            "pages": "2162-2164",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Severe2019-nCoV Remdesivir RCT",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04257656",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Mild / Moderate 2019-nCoV Remdesivir RCT",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Two Ebola treatments halve deaths in trial in DRC outbreak",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Dyer",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "BMJ",
            "volume": "366",
            "issn": "August",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1136/bmj.l5140",
                    "10.1136/bmj.l5140"
                ]
            }
        },
        "BIBREF15": {
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Cell Res",
            "volume": "",
            "issn": "",
            "pages": "2019-2021",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Arbidol as a broad-spectrum antiviral: An update",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Blaising",
                    "suffix": ""
                },
                {
                    "first": "SJ",
                    "middle": [],
                    "last": "Polyak",
                    "suffix": ""
                },
                {
                    "first": "EI",
                    "middle": [],
                    "last": "P\u00e9cheur",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antiviral Res",
            "volume": "107",
            "issn": "1",
            "pages": "84-94",
            "other_ids": {
                "DOI": [
                    "10.1016/j.antiviral.2014.04.006",
                    "10.1016/j.antiviral.2014.04.006"
                ]
            }
        },
        "BIBREF17": {
            "title": "Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04260594",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "A prospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04255017",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection (ELACOI)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04252885",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "The clinical study of carrimycin on treatment patients with Covid-19",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04286503",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Oseltamivir Treatment of Influenza in Children",
            "authors": [
                {
                    "first": "TM",
                    "middle": [],
                    "last": "Uyeki",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Infect Dis",
            "volume": "66",
            "issn": "10",
            "pages": "1501-1503",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "2019 Novel Coronavirus\u2014Important Information for Clinicians",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "del Rio",
                    "suffix": ""
                },
                {
                    "first": "PN",
                    "middle": [],
                    "last": "Malani",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.1490"
                ]
            }
        },
        "BIBREF23": {
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "1-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Various combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID-19: A Randomized Control Trial (THDMS-COVID19)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04303299",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Okubo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Isono",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Asano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sato",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Anticancer Res",
            "volume": "39",
            "issn": "11",
            "pages": "5891-5901",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): Study protocol for a randomized controlled trial",
            "authors": [
                {
                    "first": "YM",
                    "middle": [],
                    "last": "Arabi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alothman",
                    "suffix": ""
                },
                {
                    "first": "HH",
                    "middle": [],
                    "last": "Balkhy",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Al-Dawood",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "AlJohani",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Al Harbi",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Trials",
            "volume": "19",
            "issn": "1",
            "pages": "1-13",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Treatment and prevention of traditional Chinese medicines (TCMs) on 2019-nCoV infection",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04251871",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04251871",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Xiyanping injection for the treatment of new coronavirus infected pneumonia",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04275388",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of the new coronavirus infection pneumonia (general and severe)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04295551",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Evaluation of Ganovo (danoprevir) combined with ritonavir in the treatment of the novel coronavirus infection",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04291729",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1-13",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2001282"
                ]
            }
        },
        "BIBREF33": {
            "title": "A Novel Coronavirus from Patients with Pneumonia in China, 2019",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "1-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Use of carrimycin in Mycobacterium tuberculosis infection resistance",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "Danoprevir: First Global Approval",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Markham",
                    "suffix": ""
                },
                {
                    "first": "SJ",
                    "middle": [],
                    "last": "Keam",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Drugs",
            "volume": "78",
            "issn": "",
            "pages": "1271-1276",
            "other_ids": {
                "DOI": [
                    "10.1007/s40265-018-0960-0",
                    "10.1007/s40265-018-0960-0"
                ]
            }
        },
        "BIBREF36": {
            "title": "Application of Chinese Medicine in Acute and Critical Medical Conditions",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "CZ",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hesse-Fong",
                    "suffix": ""
                },
                {
                    "first": "JG",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "CS",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Am J Chin Med",
            "volume": "47",
            "issn": "6",
            "pages": "1223-1235",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Interferon-Stimulated Genes: A Complex Web of Host Defenses NIH Public Access",
            "authors": [
                {
                    "first": "WM",
                    "middle": [],
                    "last": "Schneider",
                    "suffix": ""
                },
                {
                    "first": "MD",
                    "middle": [],
                    "last": "Chevillotte",
                    "suffix": ""
                },
                {
                    "first": "CM",
                    "middle": [],
                    "last": "Rice",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "",
            "volume": "32",
            "issn": "",
            "pages": "513-545",
            "other_ids": {
                "DOI": [
                    "10.1146/annurev-immunol-032713-120231"
                ]
            }
        },
        "BIBREF38": {
            "title": "Application of Xiyanping in treatment of infantile rotavirus diarrhea",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "J Hainan Med Univ",
            "volume": "22",
            "issn": "13",
            "pages": "113-115",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04252274",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice",
            "authors": [
                {
                    "first": "JR",
                    "middle": [],
                    "last": "Santos",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Curran",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Navarro-Mercade",
                    "suffix": ""
                },
                {
                    "first": "MF",
                    "middle": [],
                    "last": "Ampuero",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Pelaez",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "P\u00e9rez-Alvarez",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "AIDS Res Hum Retroviruses",
            "volume": "35",
            "issn": "6",
            "pages": "513-518",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Pharmacokinetics and Pharmacodynamics of cobicistat GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity",
            "authors": [
                {
                    "first": "AA",
                    "middle": [],
                    "last": "Mathias",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "German",
                    "suffix": ""
                },
                {
                    "first": "BP",
                    "middle": [],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jain",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "West",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Warren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "BP",
                    "middle": [],
                    "last": "Kearney",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin Pharmacol Ther",
            "volume": "87",
            "issn": "3",
            "pages": "322-329",
            "other_ids": {
                "DOI": [
                    "10.1038/clpt.2009.228"
                ]
            }
        },
        "BIBREF42": {
            "title": "Efficacy and safety of IFN-\u03b12\u03b2 in the treatment of novel coronavirus patients",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04293887",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "The efficacy and safety of thalidomide combined with low-dose hormones in the treatment of severe Covid-19",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04273581",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February 2003",
            "authors": [
                {
                    "first": "NS",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "BJ",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "YM",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "LLM",
                    "middle": [],
                    "last": "Poon",
                    "suffix": ""
                },
                {
                    "first": "ZH",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "KH",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet",
            "volume": "362",
            "issn": "9393",
            "pages": "1353-1358",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (Covid-19) pneumonia",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04273529",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF46": {
            "title": "New Medical Indications for Thalidomide and its Derivatives New Medical Indications for Thalidomide and its Derivatives",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Newfield",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "The Science Journal of the Lander College of Arts and Sciences",
            "volume": "12",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF47": {
            "title": "Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure (Steroids-SARI)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04244591",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF48": {
            "title": "Clinical recommendations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jia",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Int J Clin Exp Med",
            "volume": "9",
            "issn": "5",
            "pages": "8865-8873",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF49": {
            "title": "Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "KC",
                    "middle": [],
                    "last": "Allen Chan",
                    "suffix": ""
                },
                {
                    "first": "DS",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "EKO",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "RWK",
                    "middle": [],
                    "last": "Chiu",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Clin Virol",
            "volume": "31",
            "issn": "4",
            "pages": "304-309",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF50": {
            "title": "Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)",
            "authors": [
                {
                    "first": "JA",
                    "middle": [],
                    "last": "Al-Tawfiq",
                    "suffix": ""
                },
                {
                    "first": "ZA",
                    "middle": [],
                    "last": "Memish",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Expert Rev Anti Infect Ther",
            "volume": "15",
            "issn": "3",
            "pages": "269-275",
            "other_ids": {
                "DOI": [
                    "10.1080/14787210.2017.1271712",
                    "10.1080/14787210.2017.1271712"
                ]
            }
        },
        "BIBREF51": {
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "497-506",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF52": {
            "title": "Vitamina C infusion for the treatment of severe 2019-nCoV infected pneumonia",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04264533",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF53": {
            "title": "A study to evaluate the efficacy and safety of Pirfenidone with novel coronavirus infection",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04282902",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF54": {
            "title": "Bevacizumab in severe or critical patients with Covid-19 pneumonia (BEST-CP)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04275414",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF55": {
            "title": "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics",
            "authors": [
                {
                    "first": "MS",
                    "middle": [],
                    "last": "Nassar",
                    "suffix": ""
                },
                {
                    "first": "MA",
                    "middle": [],
                    "last": "Bakhrebah",
                    "suffix": ""
                },
                {
                    "first": "SA",
                    "middle": [],
                    "last": "Meo",
                    "suffix": ""
                },
                {
                    "first": "MS",
                    "middle": [],
                    "last": "Alsuabeyl",
                    "suffix": ""
                },
                {
                    "first": "WA",
                    "middle": [],
                    "last": "Zaher",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Eur Rev Med Pharmaco",
            "volume": "22",
            "issn": "15",
            "pages": "4956-4961",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF56": {
            "title": "Fingolimod in COVID-19",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04280588",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF57": {
            "title": "Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild coronavirus pneumonia (COVID-19)",
            "authors": [],
            "year": null,
            "venue": "Identifier NCT04273763",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF58": {
            "title": "The emerging role of vitamin C as a treatment for sepsis",
            "authors": [
                {
                    "first": "MG",
                    "middle": [],
                    "last": "Kashiouris",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "L\u2019heureux",
                    "suffix": ""
                },
                {
                    "first": "CA",
                    "middle": [],
                    "last": "Cable",
                    "suffix": ""
                },
                {
                    "first": "BJ",
                    "middle": [],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "SW",
                    "middle": [],
                    "last": "Leichtle",
                    "suffix": ""
                },
                {
                    "first": "AA",
                    "middle": [],
                    "last": "Fowler",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nutrients",
            "volume": "12",
            "issn": "2",
            "pages": "1-16",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF59": {
            "title": "Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Fei",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Vanderlaan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Angiogenesis",
            "volume": "7",
            "issn": "4",
            "pages": "335-345",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF60": {
            "title": "Repurposing host-based therapeutics to control coronavirus and influenza virus",
            "authors": [
                {
                    "first": "CC",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "XJ",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "HCR",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drug Discov Today",
            "volume": "24",
            "issn": "3",
            "pages": "726-736",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2019.01.018",
                    "10.1016/j.drudis.2019.01.018"
                ]
            }
        },
        "BIBREF61": {
            "title": "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "De Clercq",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Drug Discov",
            "volume": "",
            "issn": "",
            "pages": "1-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF62": {
            "title": "Slew of trials launch to test coronavirus treatments in China",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Maxmen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "78",
            "issn": "",
            "pages": "37-348",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF63": {
            "title": "Drug Repurposing for Viral Infectious Diseases: How Far Are We?",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Mercorelli",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Pal\u00f9",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Loregian",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Trends Microbiol",
            "volume": "26",
            "issn": "10",
            "pages": "865-876",
            "other_ids": {
                "DOI": [
                    "10.1016/j.tim.2018.04.004",
                    "10.1016/j.tim.2018.04.004"
                ]
            }
        }
    }
}